Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line nivolumab versus investigator's choice chemotherapy in PD-L1-positive advanced non-small cell lung cancer
jRCT2080222595Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Ono Pharmaceutical. Started Sep 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222595.